Windlas Biotech Limited

Company Profile

Windlas Biotech Limited had its IPO on under the ticker symbol WINDLAS.

The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Windlas Biotech Limited has a staff strength of 1,049 employees.

Stock update

Shares of Windlas Biotech Limited opened at ₹373.05 at the start of the last trading session i.e. 2023-09-13.

The stocks traded within a range of ₹347.85 - ₹374.45, and closed at ₹357.9.

This is a -3.45% slip from the previous day's closing price.

A total volume of 5,898 shares were traded at the close of the day’s session.

In the last one week, shares of Windlas Biotech Limited have slipped by -7.09%.

Windlas Biotech Limited's Key Ratios

Windlas Biotech Limited has a market cap of ₹7.45 billion, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months Windlas Biotech Limited’s revenue was ₹5.38 billion with a gross profit of ₹0 and an EBITDA of ₹634.17 million. The EBITDA ratio measures Windlas Biotech Limited's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Windlas Biotech Limited’s operating margin was 9.44% while its return on assets stood at 5.87% with a return of equity of 10.7%.

In Q2, Windlas Biotech Limited’s quarterly earnings growth was a positive 28.7% while revenue growth was a positive 20.7%.

Windlas Biotech Limited’s PE and PEG Ratio

Forward PE

0

Trailing PE

17.0677

PEG

Its diluted EPS in the last 12-months stands at ₹20.99 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Windlas Biotech Limited’s profitability.

Windlas Biotech Limited stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

Windlas Biotech Limited stock pays annual dividends of ₹0 per share, indicating a yield of 1.11% and a payout ratio of 16.68%.

Balance sheet and cash flow metrics

Total Assets

₹5.29 billion

Total Liabilities

₹1.21 billion

Operating Cash Flow

₹0

Capital Expenditure

₹0

Dividend Payout Ratio

16.68%

Windlas Biotech Limited ended 2025 with ₹5.29 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹5.29 billion while shareholder equity stood at ₹4.02 billion.

Windlas Biotech Limited ended 2025 with ₹0 in deferred long-term liabilities, ₹1.21 billion in other current liabilities, in common stock, ₹1.76 billion in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹36.86 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹1.09 million.

Windlas Biotech Limited’s total current assets stands at ₹3.54 billion while long-term investments were ₹0 and short-term investments were ₹1.30 billion. Its net receivables were ₹1.17 billion compared to accounts payable of ₹877.43 million and inventory worth ₹747.38 million.

In 2025, Windlas Biotech Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.

Comparatively, Windlas Biotech Limited paid ₹0.17 in dividends in 2025.

Other key metrics

Current Trading Price

₹357.9

52-Week High

₹420.85

52-Week Low

₹212.15

Analyst Target Price

₹

Windlas Biotech Limited stock is currently trading at ₹357.9 per share. It touched a 52-week high of ₹420.85 and a 52-week low of ₹420.85. Analysts tracking the stock have a 12-month average target price of ₹.

Its 50-day moving average was ₹347.44 and 200-day moving average was ₹278.13 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 6281.8% of the company’s stock are held by insiders while 1050.8% are held by institutions.